Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 82

The will power of binding death nominations

There have been many articles in the media on disputes between SMSF trustees who are members of the same family. Judging by the outcomes, my recommendation is to put formal arrangements in place if you want your wishes to be respected in the event of your death.

Contrary to popular belief, superannuation assets do not automatically form part of a person’s estate pursuant to a will. If you want your superannuation to be distributed as part of your estate, you will need to check the wording of the Trust Deed and create a binding death benefit nomination (BDBN).

The way superannuation savings will be paid from an SMSF, in the event of death, is based on the SMSF’s Trust Deed. As well as stating how your benefits can be received by you while you’re alive, it should spell out how they will be distributed when you die.

The complication with SMSFs is that under superannuation law, it is not compulsory for an SMSF to have a BDBN. Without it, the surviving members in your SMSF determine who your benefit will be paid to. This may not be a problem if there is only you and your spouse and both want each other as beneficiaries. But what if you want some or all of your superannuation to go to your children?

As the BDBN is not compulsory, there are no restrictions on what it can contain. Normally a BDBN needs to be witnessed by two individuals who are not beneficiaries to the estate. It also needs to be updated every three years for it to remain valid, but even here there are exceptions. The SMSF Trust Deed can spell out under what terms a BDBN will be accepted. For example, it can offer a BDBN that does not have to be updated on a regular basis (a non-lapsing binding nomination) or does not need to be witnessed by two people. A non-lapsing nomination remains valid until the member changes it or revokes it. Please talk to a lawyer on what you should put in your Trust Deed as well as in a BDBN.

The two court decisions described below show how disputes were resolved both with and without a BDBN.

Ioppolo & Hesford v Conti [2013] WASC 389

Mr and Mrs Conti were trustees of their SMSF but were estranged. Mrs Conti made a will stating her superannuation entitlements were to go to her four children and expressly stated she did not want any of it to go to her estranged husband. She did not have a BDBN. The terms of their Trust Deed were that in the absence of a BDBN, the surviving trustee could use their discretion to pay the benefit. Mr Conti paid Mrs Conti’s benefit to himself. Mrs Conti’s children took action against their father. The court ruled in Mr Conti’s favour as he acted within the requirements of the trust deed. Mrs Conti’s will carried no weight in the court’s decision.

Wooster v Morris [2013] VSC 934

Mr Morris and his second wife were trustees of their SMSF. Mr Morris made a BDBN in March 2008 in favour of his daughters from his first marriage. Mr Morris died in February 2010. Mrs Morris decided that the BDBN was not binding and paid herself all of Mr Morris’ superannuation entitlement. The daughters took action against her. The court found in favour of the daughters, but because Mrs Morris controlled the SMSF, it took many years for Mr Morris’ daughters to claim their benefit and their court costs. Unfortunately Mrs Morris died and her estate filed for bankruptcy which consequently left the daughters with a large shortfall in their entitlements.

In conclusion, the correct wording in both an SMSF’s Trust Deed and a BDBN are critical to ensure that your wishes are carried out in timely manner.


Monica Rule is the author of The Self Managed Super Handbook. Monica is running an SMSF seminar in Sydney on 7 November 2014, with special guests Noel Whittaker, Graham Hand and Chris Cuffe. For more details visit


Limits to a will’s power over an SMSF

SMSFs the new battleground in family disputes

Six common estate planning errors


Most viewed in recent weeks

Coronavirus and a roadmap for infected investing

As much as value investors with spare cash want to jump on undervalued companies, it's probably not the time to buy the dip in the market just yet as the US braces for coronavirus's full impact.

Why we’re not buying the market yet

The Australian market bounced back last Friday (13th) and Monday (16th) tempting analysts to call the bottom of the coronavirus scare. This is too early as the impact on companies is not yet evident.

Douglass on coronavirus: 'Expect volatility but don't panic'

As investors hit the panic button, Magellan's Hamish Douglass is staying his course, advising attendees at last week's Investor Evening to sit tight and take a long-term view.

Drawdown reductions needed for retirees - UPDATED POLICY

During the GFC, in the face of rapid falls in super balances, the minimum drawdowns required for pensions were reduced by 50% to help preserve overall retirement savings. It's time for a repeat.

What are the possible economic effects of COVID-19 on the world economy?

In a widely-quoted scenario using estimated attack and fatality rates of coronavirus, about 0.07% of the population of the US dies. That's about 230,000 people, which the market is not ready for.

Note to Australia: be more French in the COVID-19 war

Andrew Baker is well-known as a superannuation consultant. Now working in the UK, he was caught in France with his family and is in lockdown. He worries Australian policy was too slow.

Latest Updates

Latest from Morningstar

Four stages of a typical bear market - but is this typical?

Bear markets primarily caused by recession fears follow a pattern, but we have never seen anything like coronavirus. If financial stimulus and medicine prove ineffective, all bets are off. 


Small business in path of COVID-19 tsunami

The turning point in this crisis will be when the number of new COVID-19 cases starts to decrease. Until then, can we mitigate the damage to businesses and the economy so that we can snap back?


What are the possible economic effects of COVID-19 on the world economy?

In a widely-quoted scenario using estimated attack and fatality rates of coronavirus, about 0.07% of the population of the US dies. That's about 230,000 people, which the market is not ready for.

Exchange traded products

Fixed interest LIT carnage makes stamping fees worse

Retail investors in fixed interest LITs now realise some structures were not the defensive portfolios they expected, but have prices reached value? Plus it's time to act on stamping fees.


Optimism among forecasts of the COVID-19 peak

This detailed analysis of infections, deaths, drugs and vaccines includes an optimistic scenario: perhaps US and Australian infection numbers will peak in early to mid-April with a decline after.



© 2020 Morningstar, Inc. All rights reserved.

The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use.
Any general advice or class service prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, has been prepared by without reference to your objectives, financial situation or needs. Refer to our Financial Services Guide (FSG) for more information. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.